Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
- Indications Aspergillosis; Blastomycosis; Coccidioidomycosis; Cryptococcosis; Histoplasmosis; Invasive bronchopulmonary aspergillosis; Mycoses; Paracoccidioidomycosis
- Focus Registrational; Therapeutic Use
- Acronyms VICAL; VITAL
- Sponsors Astellas Pharma; Basilea Pharmaceutica
- 14 Dec 2021 Results Post-Hoc Analysis from the VITAL and SECURE, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 29 Apr 2021 Results of post-hoc analysis of two studies (SECURE & VITAL) published in the Clinical Infectious Diseases.
- 19 Nov 2020 Data were used from SECURE and VITAL studies to assess Cost-Effectiveness of Isavuconazole in the Treatment of Invasive Fungal Infections in Portugal presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research